Last year, investors scrambled to invest in newly floated biotechs. This, together with a brisk licensing market and policy tailwinds, helped boost the sector, even as an expected M&A boom was late to materialize.
References
Morrison, C. Fresh from the biotech pipeline—2017. Nat. Biotechnol. 36, 131–136 (2018).
Dolgin, E. Epic $12 billion deal and FDA's approval raise CAR-T to new heights. Nat. Biotechnol. 35, 891–892 (2017).
FTC. Mallinckrodt will pay $100 million to settle FTC, state charges it illegally maintained its monopoly of specialty drug used to treat infants. https://www.ftc.gov/news-events/press-releases/2017/01/mallinckrodt-will-pay-100-million-settle-ftc-state-charges-it (Federal Trade Commission, 18 January 2017).
Garber, K. Tissue-agnostic cancer drug pipeline grows, despite doubts. Nat. Rev. Drug Discov. 17, 227–229 (2018).
Morrison, C. Alnylam prepares to land first RNAi drug approval. Nat. Rev. Drug Discov. 17, 156–157 (2018).
Ellis, S. To keep biotechs trading at home, China pilots new stock market rules. Nat. Biotechnol. 36, 384 (2018).
Author information
Authors and Affiliations
Supplementary information
Supplementary Table 1
List of publicly traded biotechs (XLS 226 kb)
Rights and permissions
About this article
Cite this article
Morrison, C., Lähteenmäki, R. Public biotech in 2017—the numbers. Nat Biotechnol 36, 576–584 (2018). https://doi.org/10.1038/nbt.4175
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.4175
- Springer Nature America, Inc.